Clinical Trials
36 trialsNCT02184416 2026-02-27
ADONIS
Pfizer
Completed
NCT02627963 2023-07-18
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
AVEO Pharmaceuticals, Inc.
Phase 3 Completed
NCT02187302 2020-05-28
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
Phase 2 Completed
NCT01195649 2019-06-04
Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy
Bayer
Terminated
NCT01411423 2018-06-06
Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan
Bayer
Completed
NCT01412671 2018-06-06
Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program
Bayer
Completed
NCT01982097 2018-02-07
SANE
Bayer
Completed
NCT01728948 2017-11-09
Sorafenib in Elderly mRCC
Bayer
Completed
NCT01557127 2017-03-28
NEXST
Bayer
Completed
NCT00467025 2016-03-23
AMG 386, 20060159 Phase 2, RCC 1st Line in Combination With Sorafenib
Amgen
Phase 2 Completed
NCT00618982 2015-12-24
Sorafenib Dose Escalation in Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT01223027 2015-12-07
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Novartis
Phase 3 Completed
NCT01012011 2015-09-21
Regulatory Post Marketing Surveillance Study on Nexavar®
Bayer
Completed
NCT01353794 2015-01-30
POWER-NEXT
Bayer
Withdrawn
NCT01508364 2015-01-21
NEXTAR
Bayer
Completed
NCT00352859 2014-12-30
Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib
Bayer
Phase 4 Terminated
NCT00492986 2014-12-30
An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma
Bayer
Phase 3 Completed
NCT00661375 2014-12-25
BAY43-9006 Phase II Study for Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT00079612 2014-12-19
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
Bayer
Phase 2 Completed
NCT00622479 2014-12-18
Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia.
Bayer
Phase 1 Terminated
NCT00678288 2014-12-11
A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib in Patients With Advanced Renal Cell Cancer.
Bayer
Phase 2 Terminated
NCT00117637 2014-10-31
BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
Bayer
Phase 2 Completed
NCT00111020 2014-08-06
Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma
Bayer
Phase 3 Completed
NCT01449825 2014-04-21
Hepatic Monitoring for Pazopanib
GlaxoSmithKline
Completed
NCT00586105 2014-04-16
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
Bayer
Phase 3 Completed
NCT00073307 2014-02-06
Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer
Bayer
Phase 3 Completed
NCT00827177 2014-01-24
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00586495 2013-12-13
Long-term Extension From RCC Phase II (11515)
Bayer
Phase 2 Completed
NCT00474786 2013-11-21
INTORSECT
Pfizer
Phase 3 Completed
NCT00110344 2013-10-11
Research Study for Patients With Metastatic Renal Cell Carcinoma
Bayer
Phase 2 Terminated
NCT01381601 2013-05-13
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
GlaxoSmithKline
Completed
NCT01381614 2013-05-13
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)
GlaxoSmithKline
Completed
NCT00771147 2012-06-15
PONDIAC
Bayer
Completed
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT00895674 2010-09-30
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Bayer
Completed
NCT00389285 2009-05-27
Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma
ZymoGenetics
Phase 1/2 Completed